Skip to content
Sign in
Health · North America

FDA approves Rasonque after trial shows longer survival in pancreatic cancer

The FDA approved Rasonque, also known as daraxonrasib, for metastatic pancreatic adenocarcinoma. In a trial of previously treated patients, median overall survival was 13.2 months with the drug, compared with 6.7 months with standard chemotherapy.

AI-assisted synthesis · Based on 4 outlets' reporting · Article text read from 2 of 4 outletsHow it's made

View timeline · 6 entries
4 outletsLatest reporting 3 min read
Coverage: Mostly CenterL 0 · C 2 · R 1 · 1 unrated
File photo
Photo: The U.S. Food and Drug Administration / Wikimedia Commons (Public domain)

What happened

Key facts

  • The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma in August (per New York Post, oncodaily.com).
  • Rasonque is the first broad RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma (per New York Post, oncodaily.com).
  • The trial included 500 patients (per oncodaily.com).
  • Median overall survival was 13.2 months for patients receiving daraxonrasib and 6.7 months for those receiving standard chemotherapy (per New York Post, oncodaily.com).
  • Trial results showed slower disease progression with Rasonque than with chemotherapy (per New York Post, oncodaily.com).

The brief

The FDA approved Rasonque, also known as daraxonrasib, for metastatic pancreatic adenocarcinoma, making it the first broad RAS-targeted therapy approved for this disease, according to the New York Post.

The approval follows results from the phase III RASolute 302 trial, which compared the drug with standard chemotherapy in patients whose metastatic cancer had already been treated. The trial enrolled 500 patients, according to OncoDaily.

Median overall survival was 13.2 months among patients who received daraxonrasib, compared with 6.7 months among those given standard chemotherapy. The New York Post also reports that the trial found slower disease progression with the drug and that declines in pain and quality of life occurred later than with chemotherapy.

The two outlets cover the same trial results from different angles. The New York Post foregrounds the FDA approval and comparative outcomes, while OncoDaily places the findings in the context of a session at Advances and Innovations in Endoscopic Oncology and Multidisciplinary GI Cancer Care.

That session explored daraxonrasib and the RASolute 302 results, linking treatment discussion with coordinated care. The care considerations described at the session included tissue acquisition, oncology treatment, symptom relief, nutrition and supportive care.

OncoDaily also reports that participants emphasized proactive management of rash, mouth sores and diarrhea, alongside monitoring for serious toxicities. These details present the treatment discussion as extending beyond drug selection to management of symptoms and treatment risks.

The New York Post describes pancreatic cancer as a disease with a difficult outlook and says Rasonque is not a cure. It cites Dr. Paul Oberstein, who called the trial results a major advance in a disease with historically few effective treatment options. The outlet also notes that work remains to improve outcomes and detect pancreatic cancer earlier.

The findings therefore combine a regulatory milestone with trial outcomes and practical care considerations: Rasonque is approved for the specified metastatic cancer, while the reported survival figures compare groups in a clinical trial. The accounts do not give a longer-term follow-up figure or a rate for the reported side effects and toxicities.

Why it matters

  • For patients with previously treated metastatic pancreatic adenocarcinoma, the trial reported median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy.
  • The New York Post reports slower disease progression and later declines in pain and quality of life with Rasonque than with chemotherapy, outcomes relevant to patients’ disease course and day-to-day well-being.
  • The session discussed symptom relief, nutrition and supportive care, as well as management of rash, mouth sores and diarrhea and monitoring for serious toxicities.

What to watch next

  • Whether further trial results report longer-term outcomes for patients treated with daraxonrasib.
  • Whether additional information reports how often rash, mouth sores, diarrhea or serious toxicities occurred.
  • Whether future evidence clarifies how Rasonque affects pain and quality-of-life outcomes over time.

How it's being covered

Coverage analysisShow details
4 source articles · 4 unique outlets
Outlet political mix: Mostly Center· 2 Center · 1 Right · 1 unrated
Where the outlets are based: US/Canada 50% · Unknown 50%
Outlet political mix
Mostly Center
Left
Center
Right
0 outlets
2 outlets
1 outlet
The marker shows coverage balance: each unique outlet counts once. 1 unrated outlet is not included.
Geography
Where the outlets covering this story are based.
4 unique outletsDominant coverage: US/Canada
How we measure coverage

How outlets' accounts compare

1 framing difference · 1 uncorroborated claim · 1 information gap
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read; 2 other outlets were checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • The New York Post emphasizes the FDA approval, the comparative clinical outcomes and the limits of the drug; OncoDaily focuses on the trial discussion and the coordination of treatment with symptom management and supportive care.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • The New York Post quotes Dr. Paul Oberstein describing the trial results as a major advance given the historically limited effective treatment options.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • The sources do not provide the trial's full design, eligibility criteria, statistical uncertainty or follow-up duration.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. The FDA approved gemcitabine for pancreatic cancer.
    Background · compiled and fact-checked by Updat3
  2. The PRODIGE 4/ACCORD 11 trial reported longer survival with FOLFIRINOX than with gemcitabine in selected patients with metastatic pancreatic cancer.
    Background · compiled and fact-checked by Updat3
  3. Researchers reported a binding pocket in mutant KRAS G12C that could be targeted by a small molecule.
    Background · compiled and fact-checked by Updat3
  4. The Cancer Genome Atlas published an analysis finding KRAS mutations in most pancreatic ductal adenocarcinomas.
    Background · compiled and fact-checked by Updat3
  5. In May 2021, the FDA approved sotorasib for certain patients with KRAS G12C-mutated non-small-cell lung cancer, the first approval of a drug that directly targeted a KRAS mutation.
    Background · from our historical context
  6. The FDA approved NALIRIFOX for first-line treatment of metastatic pancreatic adenocarcinoma.
    Background · compiled and fact-checked by Updat3

How we got here

In January 2011, the PRODIGE 4/ACCORD 11 trial reported that FOLFIRINOX improved survival over gemcitabine in selected patients with metastatic disease; the FDA approved gemcitabine for pancreatic cancer in 1996.

In February 2024, the FDA approved NALIRIFOX for first-line treatment of metastatic pancreatic adenocarcinoma after the NAPOLI-3 trial found longer median overall survival with that regimen than with gemcitabine plus nab-paclitaxel. The Cancer Genome Atlas’ 2017 analysis of pancreatic cancer found KRAS mutations in most pancreatic ductal adenocarcinomas.

Related developments1 story

Original sources

4 articles from 4 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.